NCT02902640 - A Non-Interventional Safety Study of Balsamic Bactrim | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

November 15, 2016

Primary Completion Date

July 31, 2017

Study Completion Date

July 31, 2017

Conditions

Bronchitis

Interventions

DRUG

Guaifenesin

Guaifenesin will be administered as per treating physician's discretion, according to local labeling. The protocol does not specify any dose, frequency, and duration of treatment.

DRUG

Sulfamethoxazole

Sulfamethoxazole will be administered as per treating physician's discretion, according to local labeling. The protocol does not specify any dose, frequency, and duration of treatment.

DRUG

Trimethoprim

Trimethoprim will be administered as per treating physician's discretion, according to local labeling. The protocol does not specify any dose, frequency, and duration of treatment.

Trial Locations (4)

15088

Clínica Providencia; Centro de Investigación de Enfermedades Respiratorias, Lima

15801

Centro de Investigaciones Medicas/Hospital Maria Auxiliadora, San Juán de Miraflores

Lima 41

Clinica de Especialidades Medicas, Lima

Clinica San Borja; Instituto de Enfermedades Respiratorias EFEH, Lima

All Listed Sponsors

lead

Hoffmann-La Roche

INDUSTRY